Co-Diagnostics, Inc. (NASDAQ: CODX) announced progress in developing Ebola PCR tests through its joint venture with CoSara Diagnostics Pvt. Ltd., according to a company statement.

The program includes two assay types: a pan-Ebola assay designed to detect multiple ebolavirus species and a multiplex assay capable of differentiating among Sudan, Taï Forest, Zaire, and Bundibugyo ebolaviruses associated with outbreaks in Central Africa.

The dual-assay strategy is intended to support outbreak response efforts, including those of potential NGO partners, subject to future development, validation, regulatory review, and deployment requirements.

"Our ability to rapidly develop and deploy molecular diagnostic solutions for emerging infectious disease threats is one of the most important differentiators of the Co-Dx platform," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.

The company is developing Ebola PCR assay workflow configurations for point-of-care environments on the Co-Dx PCR point-of-care platform. This would represent the first blood-based pathogen assay designed for use on the Co-Dx PCR Pro, expanding the platform's capabilities beyond swab-based infectious disease testing.

The Co-Dx PCR platform, including the PCR Home, PCR Pro, mobile app, and associated tests, remains subject to review by the FDA and other regulatory bodies and is not yet available for sale.

Co-Diagnostics is a Utah-based molecular diagnostics company that develops, manufactures and markets diagnostic technologies for tests designed using detection and analysis of nucleic acid molecules.